Iloprost

Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research[1][2][3][4].

Product Specifications

CAS Number

[78919-13-8]

Product Name Alternative

Ciloprost; ZK 36374

UNSPSC

12352211

Hazard Statement

H302, H312, H332

Target

Endogenous Metabolite; Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease

Field of Research

Endocrinology; Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Iloprost.html

Purity

99.76

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)CCC/C=C1C[C@@]2([H])C[C@@H](O)[C@H](/C=C/[C@@H](O)C(C)CC#CC)[C@@]2([H])C\1

Molecular Formula

C22H32O4

Molecular Weight

360.49

Precautions

H302, H312, H332

References & Citations

[1]Kowalczyk-Zieba I, et al. Iloprost affects in vitro maturation and developmental competence of bovine oocytes. Theriogenology. 2020 Nov;157:286-296. |[2]Hildebrand M. Pharmacokinetics of iloprost and cicaprost in mice. Prostaglandins. 1992 Nov;44 (5) :431-42.|[3]Olave N, et al. Iloprost attenuates hyperoxia-mediated impairment of lung development in newborn mice. Am J Physiol Lung Cell Mol Physiol. 2018 Oct 1;315 (4) :L535-L544. |[4]Schneider MR, et al. Effects of prostacyclin analogues in in vivo tumor models. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:901-8.